The estimated Net Worth of Reshma Kewalramani is at least $92 Milión dollars as of 30 July 2024. Reshma Kewalramani owns over 15,202 units of Vertex Pharmaceuticals stock worth over $43,187,098 and over the last 6 years he sold VRTX stock worth over $42,044,851. In addition, he makes $6,816,940 as President, Chief Executive Officer a Director at Vertex Pharmaceuticals.
Reshma has made over 27 trades of the Vertex Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 15,202 units of VRTX stock worth $7,677,010 on 30 July 2024.
The largest trade he's ever made was exercising 17,135 units of Vertex Pharmaceuticals stock on 15 December 2023 worth over $3,115,657. On average, Reshma trades about 3,481 units every 48 days since 2018. As of 30 July 2024 he still owns at least 90,970 units of Vertex Pharmaceuticals stock.
You can see the complete history of Reshma Kewalramani stock trades at the bottom of the page.
Dr. Reshma Kewalramani M.D. has been appointed as President, Chief Executive Officer, Director of the company. Effective April 01, 2020. and she is no longer as an Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer of the Company, Effective April 01, 2020. She was our Senior Vice President, Late Development from February 2017 until April 2018. From August 2004 to January 2017 she served in roles of increasing responsibility at Amgen Inc., most recently as Vice President Global Clinical Development, Nephrology & Metabolic Therapeutic Area and as Vice President, U.S. Medical Organization. Dr. Kewalramani is the industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee. She completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Women’s Hospital combined program. Dr. Kewalramani holds a B.A. from Boston University and an M.D. from Boston University School of Medicine.
As the President, Chief Executive Officer a Director of Vertex Pharmaceuticals, the total compensation of Reshma Kewalramani at Vertex Pharmaceuticals is $6,816,940. There are 2 executives at Vertex Pharmaceuticals getting paid more, with Jeffrey Leiden having the highest compensation of $18,790,000.
Reshma Kewalramani is 46, he's been the President, Chief Executive Officer a Director of Vertex Pharmaceuticals since 2020. There are 21 older and 3 younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.
Reshma's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden a Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include: